고셔병 치료제 시장 : 기회, 성장 동인, 산업 동향 분석 및 예측(2024-2032년)

The Global Gaucher Disease Drugs Market was valued at approximately USD 1.6 billion in 2023 and is anticipated to grow at a CAGR of 2.9% from 2024 to 2032. Gaucher disease is a rare, inherited metabolic condition caused by an enzyme glucocerebrosidase deficiency, leading to the accumulation of glucocerebroside in organs like the spleen, liver, and bone marrow. This results in symptoms such as anemia, fatigue, bone pain, and organ enlargement. The rising prevalence of Gaucher disease, along with increasing demand for effective treatments, is driving market growth.

Key market drivers include rising awareness about Gaucher disease, growing investments in treatment development, and increasing government support for rare disease therapies. These factors are promoting advancements in enzyme replacement therapy (ERT) and substrate replacement therapy (SRT).

The overall Gaucher Disease Drugs Industry is categorized based on Disease Type, Therapy Type, Distribution Channel, and Region.

With respect to disease type, the type 1 segment is projected to reach USD 1.8 billion by 2032 due to its higher prevalence. Type 1 Gaucher disease is primarily treated with enzyme replacement therapies, which supply a synthetic version of glucocerebrosidase, preventing the accumulation of harmful glucocerebroside. The introduction of oral therapies targeting Type 1 is expected to present growth opportunities.

Based on therapy type, enzyme replacement therapy (ERT) accounted for USD 1.2 billion in 2023 and is anticipated to remain a dominant segment. ERT helps reduce the accumulation of Gaucher cells in vital organs, alleviating symptoms such as enlarged spleen and liver and improving hematological parameters like hemoglobin levels and platelet counts. This helps manage complications such as anemia, bone damage, and organ dysfunction, ultimately improving the quality of life for patients.

The market is further segmented by distribution channel, with hospital pharmacies expected to reach USD 1 billion by 2032. Hospital pharmacies play a key role in offering the latest therapies, providing specialized knowledge, and ensuring high-quality medication management. Their expertise and strict quality control protocols contribute to enhanced treatment outcomes.

In the U.S., the Gaucher disease drugs market is projected to reach USD 711.6 million by 2032. The country's strong pharmaceutical R&D capabilities and a supportive regulatory environment, such as the FDA's Orphan Drug Act, contribute significantly to market growth, facilitating the development and approval of new treatments for Gaucher disease.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of Gaucher disease
    • 3.2.1.2 Growing investments for developing Gaucher disease therapies
    • 3.2.1.3 Increasing awareness towards timely diagnosis and treatment
    • 3.2.1.4 Rising government support for rare disease therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of therapies
    • 3.2.2.2 Presence of stringent regulatory approval procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Type 1
• 5.3 Type 3

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Enzyme replacement therapy
• 6.3 Substrate replacement therapy
• 6.4 Other therapy types

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Johnson and Johnson
• 9.2 Pfizer Inc.
• 9.3 Sanofi
• 9.4 Takeda Pharmaceutical Company Limited
• 9.5 Zywie LLC